{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:09:13Z","timestamp":1787580553264,"version":"build-2736575974"},"reference-count":55,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.annonc.2026.04.003","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:28:15Z","timestamp":1775896095000},"page":"1106-1119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-7704","authenticated-orcid":false,"given":"D.","family":"Juric","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Reising","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Vervier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2796-1042","authenticated-orcid":false,"given":"E.M.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1294-0027","authenticated-orcid":false,"given":"C.F.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ghaznawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Taran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2026.04.003_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.annonc.2026.04.003_bib2","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"33","key":"10.1016\/j.annonc.2026.04.003_bib4","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","article-title":"Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer","volume":"29","author":"Miller","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.003_bib5","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2174\/156800908786733504","article-title":"The PIK3CA gene as a mutated target for cancer therapy","volume":"8","author":"Gustin","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"issue":"13 suppl","key":"10.1016\/j.annonc.2026.04.003_bib6","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1158\/1538-7445.AM2019-4458","article-title":"Abstract 4458: Clinical significance of PIK3CA and ESR1 mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"79","author":"Tolaney","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.003_bib7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","article-title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Di Leo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2026.04.003_bib8","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1002\/jcb.26687","article-title":"The prognostic value of PI3K mutational status in breast cancer: a meta-analysis","volume":"119","author":"Sobhani","year":"2018","journal-title":"J Cell Biochem"},{"issue":"10","key":"10.1016\/j.annonc.2026.04.003_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1200\/JCO.2017.74.8301","article-title":"Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data","volume":"36","author":"Zardavas","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.003_bib10","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1186\/s12885-022-10078-5","article-title":"PIK3CA mutation status, progression and survival in advanced HR+\/HER2\u2212 breast cancer: a meta-analysis of published clinical trials","volume":"22","author":"Fillbrunn","year":"2022","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.003_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","article-title":"Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"6466","key":"10.1016\/j.annonc.2026.04.003_bib12","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aaw9032","article-title":"Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors","volume":"366","author":"Vasan","year":"2019","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.003_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-23-0704","article-title":"Allosteric PI3K\u03b1 inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations","volume":"14","author":"Varkaris","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2026.04.003_bib14","series-title":"Determination of the PI3K\u03b1 selective inhibitor alpelisib mechanism of action and efficacy in ER+\/PIK3CA mutant breast cancer pre-clinical models","author":"Fritsch","year":"2018"},{"key":"10.1016\/j.annonc.2026.04.003_bib15","series-title":"East Hanover","year":"2024"},{"key":"10.1016\/j.annonc.2026.04.003_bib16","series-title":"Piqray [summary of product characteristics]","year":"2020"},{"issue":"20","key":"10.1016\/j.annonc.2026.04.003_bib17","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.003_bib18","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.04.003_bib19","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/2159-8290.CD-21-1696","article-title":"Alpelisib monotherapy for PI3K-altered, pretreated advanced breast cancer: a phase II atudy","volume":"12","author":"Savas","year":"2022","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.003_bib20","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13058-020-01328-0","article-title":"Clinical implications of prospective genomic profiling of metastatic breast cancer patients","volume":"22","author":"van Geelen","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.003_bib21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.annonc.2023.01.009","article-title":"Genomic characterisation of hormone receptor-positive breast cancer arising in very young women","volume":"34","author":"Luen","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.003_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ccell.2018.08.008","article-title":"The genomic landscape of endocrine-resistant advanced breast cancers","volume":"34","author":"Razavi","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.003_bib23","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s43018-020-0047-1","article-title":"Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors","volume":"1","author":"Razavi","year":"2020","journal-title":"Nat Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2026.04.003_bib24","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2018.1778","article-title":"Association of somatic driver alterations with prognosis in postmenopausal, hormone receptor-positive, HER2-negative early breast cancer: a secondary analysis of the BIG 1-98 randomized clinical trial","volume":"4","author":"Luen","year":"2018","journal-title":"JAMA Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2026.04.003_bib25","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1158\/1078-0432.CCR-20-0224","article-title":"ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: a combined analysis of the phase III SoFEA and EFECT trials","volume":"26","author":"Turner","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.003_bib26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/EDBK_237715","article-title":"Molecular testing in breast cancer","volume":"39","author":"Litton","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"10.1016\/j.annonc.2026.04.003_bib27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O\u2019Leary","year":"2018","journal-title":"Cancer Discov"},{"issue":"4 suppl","key":"10.1016\/j.annonc.2026.04.003_bib28","first-page":"PD15","volume":"82","author":"Turner","year":"2021","journal-title":"Cancer Res"},{"issue":"25","key":"10.1016\/j.annonc.2026.04.003_bib29","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.04.003_bib30","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1158\/0008-5472.CAN-20-3232","article-title":"Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3K\u03b1 inhibitors","volume":"81","author":"Cai","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.003_bib31","series-title":"Pooled ctDNA analysis of the MONALEESA phase III advanced breast cancer trials","author":"Andr\u00e9","year":"2020"},{"key":"10.1016\/j.annonc.2026.04.003_bib32","series-title":"Characterizing demographics, clinical, and genomic characteristics for US patients with HR+, HER2- metastatic breast cancer following progression on a CDK4 and 6 inhibitor","author":"Andr\u00e9","year":"2021"},{"issue":"7757","key":"10.1016\/j.annonc.2026.04.003_bib33","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","article-title":"Genomic characterization of metastatic breast cancers","volume":"569","author":"Bertucci","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.003_bib34","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","article-title":"PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer","volume":"10","author":"Costa","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2026.04.003_bib35","series-title":"Loss of ASXL1 tumor suppressor promotes resistance to CDK4\/6 inhibitors in ER+ breast cancer","author":"Sudhan","year":"2021"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.003_bib36","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2159-8290.CD-19-1390","article-title":"The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4\/6 inhibitors in patients with hormone receptor-positive metastatic breast cancer","volume":"10","author":"Wander","year":"2020","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.annonc.2026.04.003_bib37","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.003_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264138","article-title":"Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors","volume":"17","author":"Milbury","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2026.04.003_bib39","series-title":"Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining","first-page":"1715","article-title":"A multi-task learning formulation for survival analysis","author":"Li","year":"2016"},{"key":"10.1016\/j.annonc.2026.04.003_bib40","series-title":"Proceedings of the Joint European Conference on Machine Learning and Knowledge Discovery in Databases","first-page":"274","article-title":"On learning matrices with orthogonal columns or disjoint supports","author":"Vervier","year":"2014"},{"key":"10.1016\/j.annonc.2026.04.003_bib41","series-title":"Differential gene mutation landscape in patients with PIK3CA-altered and non-altered hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the SOLAR-1 clinical study","author":"Juric","year":"2022"},{"key":"10.1016\/j.annonc.2026.04.003_bib42","series-title":"Alpelisib + fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2\u2212) advanced breast cancer (ABC): biomarker analyses by next-generation sequencing from the SOLAR-1 study","author":"Juric","year":"2022"},{"key":"10.1016\/j.annonc.2026.04.003_bib43","series-title":"Genomic landscape of HER2-negative advanced or metastatic breast cancer with PIK3CA gain-of-function mutations","author":"Xi","year":"2021"},{"issue":"6","key":"10.1016\/j.annonc.2026.04.003_bib44","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/jcm11061605","article-title":"High mutation burden in ER-positive\/HER2-negative\/luminal breast cancers","volume":"11","author":"Voutsadakis","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.003_bib45","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.18632\/aging.102701","article-title":"PIK3CA gene mutations in the helical domain correlate with high tumor mutation burden and poor prognosis in metastatic breast carcinomas with late-line therapies","volume":"12","author":"Tang","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.003_bib46","first-page":"1","article-title":"MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers","volume":"5","author":"Dey","year":"2015","journal-title":"Am J Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.003_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2814","article-title":"Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers","volume":"13","author":"Xu","year":"2011","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.annonc.2026.04.003_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.936550","article-title":"RAD21 confers poor prognosis and affects ovarian cancer sensitivity to poly(ADP-ribose)polymerase inhibitors through DNA damage repair","volume":"12","author":"Gou","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2026.04.003_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.144966","article-title":"Cohesin subunit RAD21: from biology to disease","volume":"758","author":"Cheng","year":"2020","journal-title":"Gene"},{"key":"10.1016\/j.annonc.2026.04.003_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/JHC.S447915","article-title":"RAD21: a key transcriptional regulator in the development of residual liver cancer","volume":"11","author":"Pang","year":"2024","journal-title":"J Hepatocell Carcinoma"},{"issue":"7-8","key":"10.1016\/j.annonc.2026.04.003_bib51","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.biocel.2007.03.022","article-title":"MDM2 and MDM4: p53 regulators as targets in anticancer therapy","volume":"39","author":"Toledo","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.annonc.2026.04.003_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.818744","article-title":"It\u2019s getting complicated\u2014a fresh look at p53-MDM2-ARF triangle in tumorigenesis and cancer therapy","volume":"10","author":"Kung","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.003_bib53","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7555\/JBR.27.20130030","article-title":"The MDM2-p53 pathway revisited","volume":"27","author":"Nag","year":"2013","journal-title":"J Biomed Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.003_bib54","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1038\/s41598-021-82542-4","article-title":"MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma","volume":"11","author":"Woodfield","year":"2021","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.annonc.2026.04.003_bib55","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/biom9040153","article-title":"The PTEN-PI3K axis in cancer","volume":"9","author":"Papa","year":"2019","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.annonc.2026.04.003_bib56","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1016\/S1470-2045(24)00673-9","article-title":"Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4\/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study","volume":"25","author":"Rugo","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342600133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092375342600133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:42:07Z","timestamp":1785876127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092375342600133X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":55,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S092375342600133X"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.003","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}